Stated plainly: KP · Shanghai ERP Biotechnology.
I want to know what the trade-off actually is rather than which option is fashionable.
I would rather have a defensible reason than a marginal improvement.
So which one, and on what grounds?
Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.
Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.
| Step | Value | Note |
|---|---|---|
| Vial price, 10 mg nominal | £34.00 | As advertised |
| Nominal cost per mg | £3.40 | 34 ÷ 10 |
| Measured content | 9.2 mg | Independent content assay |
| Cost per actual mg | £3.70 | 34 ÷ 9.2 |
| Dead-space loss, 20 draws | 4 % | 80 µL of a 2 mL fill |
| Cost per delivered mg | £3.85 | 3.70 ÷ 0.96 |
| First vial, with £110 assay | £14.85 | Testing dominates a single vial |
Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.
Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.
One laboratory, one method, one submission. Otherwise it is not a comparison.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.
Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.
It helps to be literal here: submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.
Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.
Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.
Compare content, not purity. Purity clusters and content does not.
edited 26 May 2025 by w_okoye — added the citation requested in comments
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.